Account
Insider Insights
14.03.2022
UK: Rare diseases economic burden ten times

The study looks at the direct, indirect and mortality-related costs of 24 rare diseases across five ...

Read more
Insider Insights
03.03.2022
NICE recommends routine use of Zejula

The National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zej...

Read more
Insider Insights
28.02.2022
UK first rare disease action plan

On 28th February 2022, Health and Social Care Secretary Sajid Javid launched England’s first Rare...

Read more
Insider Insights
24.02.2022
Legislation-extends-CPR-and-CTS-membership

The National Recovery and Resilience Plan had extended the membership to the CPR and CTS until 28th...

Read more
Insider Insights
21.02.2022
CNAM spending on reimbursed medicines

Reimbursed spending by the CNAM on out-patient care (including care from general practitioners [GPs]...

Read more
Insider Insights
16.02.2022
AIFA announces reimbursement of oral SMA treatment

The Italian Medicines Agency (AIFA) has announced that Roche’s Evyrsdi (risdiplam) is reimbursed w...

Read more
Insider Insights
15.02.2022
NICE recommends CDF use of dostarlimab

The CDF allows patients to access a new treatment while further data is collected on its clinical an...

Read more
Insider Insights
10.02.2022
Institute of Cancer Research labels NICE

In a statement the ICR said that it welcomes some of the changes, but that it wants to “see furthe...

Read more
Insider Insights
10.02.2022
Reimbursement rate of gliptins revised downwards

In line with legislation published in the Official Journal (Journal Officiel) on 1st February 2022, ...

Read more
Insider Insights
07.02.2022
NHS England announces access deal for Libmeldy

The news comes after the health service negotiated a “significant confidential discount” to the ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.